Drug Trial Radar · NCT06150183
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
41
Actual
Start
Nov 30, 2023
Primary completion
Aug 18, 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- Collaborators
- Genmab
- First posted
- Nov 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this first-in-human study is to find out if BNT314 is safe when it is used alone in patients with different types of cancer. This is a dose escalation study in which patients will be assigned to multiple dose levels (DLs) of BNT314 given alone. By escalating the dose with a small group of patients, the Maximum Tolerated Dose which is the highest dose with acceptable safety and manageable side effects, or the maximum administered dose will be investigated.
Conditions
- Advanced Malignant Solid Tumor
Interventions
BNT314Biological
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of dose-limiting toxicity within a cohortTime frame: 21 days from the first dose administration
- Number and percentage of patients with occurrence of treatment-emergent adverse events (TEAEs) including Grade ≥ 3, serious, fatal TEAE by relationshipTime frame: from first dose of study treatment to 90 days after last dose of study treatment
- Number and percentage of patients with occurrence of dose reduction and discontinuation of investigational medicinal product (IMP) due to TEAETime frame: from first dose of study treatment to 90 days after last dose of study treatment
- Number and percentage of patients with occurrence of Grade ≥ 3 abnormal safety laboratory parametersTime frame: from first dose of study treatment to 90 days after last dose of study treatment
Locations
14 sites in 6 countries. Site status is shown where the registry gives one.
START Midwest
Grand Rapids, Michigan
Carolina BioOncology Institute, LLC
Huntersville, North Carolina
Cleveland Clinic
Cleveland, Ohio
GZA Ziekenhuizen
Antwerp, Belgium
CHU de Liège
Liège, Belgium
Rigshospitalet
Copenhagen, Denmark
National Cancer Center Hospital East
Kashiwanoha, Japan
Hospital Quironsalud Barcelona (NEXT Barcelona)
Barcelona, Spain
Hospital Fund. Jiménez Dia
Madrid, Spain
Hospital HM Univ. Sanchinarro, Ensayos START
Madrid, Spain
Clinica Universidad de Navarra
Pamplona, Spain
Royal Marsden Hospital - London
London, United Kingdom
The Christie Hospital
Manchester, United Kingdom
Northern Centre for Cancer Care
Newcastle, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.